ArticleAntimicrobial agents and chemotherapy1998
In vitro activity of a new ketolide antibiotic, HMR 3647, against Chlamydia pneumoniae.
Article in Antimicrobial agents and chemotherapy, 1998. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed.
- Controlled trial of a 5-day course of telithromycin versus doxycycline for treatment of mild to moderate scrub typhus.Antimicrobial agents and chemotherapy · 2007Trial
- Efficacy and safety of telithromycin 800 mg once daily for 7 days in community-acquired pneumonia: an open-label, multicenter study.BMC infectious diseases · 2005Trial
- Intrapulmonary pharmacokinetics of telithromycin, a new ketolide, in healthy Japanese volunteers.Antimicrobial agents and chemotherapy · 2002Trial
- Bronchopulmonary disposition of the ketolide telithromycin (HMR 3647).Antimicrobial agents and chemotherapy · 2001Trial
- Fungal endophytes of turmeric (Curcuma longa L.) and their biocontrol potential against pathogens Pythium aphanidermatum and Rhizoctonia solani.World journal of microbiology & biotechnology · 2018Article
- In vitro activity of CEM-101, a new fluoroketolide antibiotic, against Chlamydia trachomatis and Chlamydia (Chlamydophila) pneumoniae.Antimicrobial agents and chemotherapy · 2010Article
- Telithromycin pharmacokinetics in rat model of diabetes mellitus induced by alloxan or streptozotocin.Pharmaceutical research · 2008Article
- Effects of Escherichia coli lipopolysaccharide on telithromycin pharmacokinetics in rats: inhibition of metabolism via CYP3A.Antimicrobial agents and chemotherapy · 2008Article
- Review
- Antibiotics for treatment of resistant gram-positive coccal infections.Indian journal of pediatrics · 2006Review
- Telithromycin in the treatment of acute bacterial sinusitis, acute exacerbations of chronic bronchitis, and community-acquired pneumonia.Therapeutics and clinical risk management · 2006Article
- Clinical pharmacokinetics of telithromycin, the first ketolide antibacterial.Clinical pharmacokinetics · 2005Review
- Telithromycin treatment of chronic Chlamydia pneumoniae infection in C57BL/6J mice.Antimicrobial agents and chemotherapy · 2004Article
- Telithromycin.Drugs · 2004Review
- Antibiotic susceptibilities of Parachlamydia acanthamoeba in amoebae.Antimicrobial agents and chemotherapy · 2002Article
- Effect of telithromycin (HMR 3647) on polymorphonuclear neutrophil killing of Staphylococcus aureus in comparison with roxithromycin.Antimicrobial agents and chemotherapy · 2002Article
- Chlamydia pneumoniae and atherosclerosis: critical assessment of diagnostic methods and relevance to treatment studies.Clinical microbiology reviews · 2002Review
- The ketolides: a critical review.Drugs · 2002Review
- Telithromycin.Drugs · 2001Article
- Macrolide resistance conferred by base substitutions in 23S rRNA.Antimicrobial agents and chemotherapy · 2001Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The in vitro activities of HMR 3647, roxithromycin, erythromycin, and azithromycin against 19 strains of Chlamydia pneumoniae were tested. The MIC at which 90% of the isolates are inhibited and the minimum bactericidal concentration at which 90% of the isolates are killed of HMR 3647 were 0.25 microgram/ml (range, 0.015 to 2 micrograms/ml). Nine recently obtained clinical isolates from children with pneumonia were more susceptible (MICs, 0.015 to 0.0625 microgram/ml) than older strains that had been passaged more extensively.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.